Prescient Therapeutics Ltd (ASX:PTX) has been issued two notices of patent allowance for its cancer drug candidate PTX-200 by the U.S. Patent and Trademark Office (USPTO).
The allowances are for “Effective treatment of tumors and cancer with triciribine and related compounds” and “Compositions including triciribines and taxanes and methods of use thereof”.
PTX-200 inhibits an important tumor survival pathway known as Akt, which plays a key role in the development of many cancers, including breast and ovarian cancer, as well as leukaemia.
The first allowance bears relevance to claims involving the intravenous dosing schedule of PTX-200, including a method for identifying and treating patients with tumors in the pancreas, ovary or colon that have highly expressed Akt.
The second allowance has allowed claims bearing particular relevance to Prescient’s ongoing breast cancer clinical trial, involving the use of PTX-200 with taxanes.
In May, Prescient raised $7 million from life-science focused Australian institutional investors by issuing shares at $0.09 each.
The company raised a further $3 million from an entitlement offer in July.
Prescient is well funded to move ahead with the three clinical trials underway for its lead cancer drug candidate PTX-200.
Proactive Investors Australia is the market leader in producing news, articles and research reports on ASX emerging companies with distribution in Australia, UK, North America and Hong Kong / China.